BioSpace News Archive

A new global study launched during World Antimicrobial Awareness Week (WAAW, 18-24 November) shows a high dependence on antibiotics for treating respiratory conditions like sore throat, which is helping to fuel antibiotic resistance - the third leading cause of death worldwide, associated with 4.95 million deaths a year.

MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today reported that the U.S. Food and Drug Administration announced the approval of the Biologics License Application (BLA) for teplizumab, an anti-CD3 monoclonal antibody that was previously developed by MacroGenics.

Universal Diagnostics today announced the results of a study evaluating putative methylation markers in biological context of early colorectal cancer (CRC) development.

Novocure (NASDAQ: NVCR) today announced 25 abstracts on Tumor Treating Fields (TTFields) therapy will be featured at the Society for Neuro-Oncology (SNO) 2022 Annual Meeting from Nov. 16 to Nov. 20 in Tampa.

Kinevant Sciences today announced that the first patient has been dosed in its RESOLVE-Lung study.

Takeda today announced that the randomized, Phase 3 PhALLCON trial met its primary endpoint, demonstrating that adult patients with newly-diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) treated with ICLUSIG® (ponatinib) plus reduced-intensity chemotherapy achieved higher rates of minimal residual disease (MRD)-negative complete remission (CR) compared to imatinib.

BARDA is seeking to support the development of broad-spectrum, oral/IV antifungal drug candidates with novel mechanisms of action that target Candida species, including Candida auris, and Aspergillus species.

RenovoRx Announces Presentations at the Advanced Interventional Management Symposium (AIMsymposium) Highlighting its Innovative RenovoTAMP ® Therapy Platform for Targeted Treatment of Cancers.

Vistagen Announces Publication in Cells Demonstrating AV-101’s Potential for Treating Levodopa-Induced Dyskinesia in Patients with Parkinson’s Disease.

Cosette Pharmaceuticals, Inc., a New Jersey-based specialty pharmaceutical company, announced the appointment of Kevin Hickey as Vice President, Brand Sales and Marketing, bolstering its executive leadership team.